Bioengineer.org news story
A new systematic review and meta-analysis published in Virology Journal has brought together the scattered clinical evidence on treating acute hepatitis C virus (HCV) infection with interferon-free, dual direct-acting antiviral (DAA) regimens, and the headline finding is striking: across fourteen studies encompassing 1,078 treated patients, the pooled rate of sustained virological response at twelve weeks after therapy (SVR12) — the standard benchmark for cure — reached 97.7 percent. The analysis also delivers a nuanced message about treatment duration. Cure rates climbed steadily as courses lengthened, from under 85 percent at four weeks to above 99 percent at eight weeks, suggesting that while ultra-short therapy remains tempting, eight weeks may represent the practical minimum for reliably eradicating recently acquired infection.
Read the full news story here.